Poxel's imeglimin meets in first Japanese Phase III for Type II diabetes

Poxel and Sumitomo said imeglimin met the primary endpoint in the Japanese Phase III TIMES 1 trial to treat Type II diabetes.

Read the full 226 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE